JIB-04
Cat.No:IJ0190 Solarbio
CAS:199596-05-9
Storage:Powder:-20℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:Off-white to yellow Solid
Qty:
Size:
{{cart_num}}
My Cart>
Small Molecule Compounds >
Inhibitors & Antagonists & Agonists >
Epigenetics >
JIB-04CAS:199596-05-9
Storage:Powder:-20℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:Off-white to yellow Solid
Qty:
Size:
CAS | 199596-05-9 |
Name | JIB-04 |
Molecular Formula | C17H13ClN4 |
Molecular Weight | 308.77 |
Solubility | Soluble in DMSO |
Purity | ≥98% |
Appearance | Off-white to yellow Solid |
Storage | Powder:-20℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
MDL | MFCD26936344 |
SMILES | ClC1=CN=C(N/N=C(C2=CC=CC=C2)/C3=NC=CC=C3)C=C1 |
Target Point | Histone Demethylase |
Passage | Epigenetics |
Background | It is a broad-spectrum selective inhibitor of Jumonji histone demethylase. |
Biological Activity | JIB-04 是 Jumonji 组蛋白去甲基酶 (Jumonji histone demethylase) 广谱抑制剂, 能抑制 JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C 和 JMJD2D 的活性, 其 IC50 值分别为 230, 340, 855, 445, 435, 1100 和 290 nM[1]。 |
IC50 | IC50: 230nM (JARID1A) , 445nM (JMJD2A) , 435nM (JMJD2B) , 1100nM (JMJD2C) , 290nM (JMJD2D) , 340nM (JMJD2E) , 855nM (JMJD3) [1] |
In Vitro | 与HBEC和PrSCs / PrEC相比,JIB-04对癌症与正常细胞的选择性一致,肺和前列腺癌细胞系的敏感性较高(IC50低至10 nM)。 JIB-04抑制细胞Jumonji脱甲基酶活性,Jumonji水平影响细胞中JIB-04的作用[1]。 JIB-04显着抑制GB细胞系和富含干细胞的培养物的增殖。 JIB-04发挥其对KDM5A的最大抑制活性,并调节参与癌细胞生长控制的基因的表达,并导致H3K4的高甲基化。此外,JIB-04(2500nM)激活自噬和凋亡途径并使PI3K失活。 JIB-04还与TMZ合作杀死GB细胞[2]。 |
In Vivo | JIB-04可显着降低小鼠癌症引起的死亡率,延长生存期[1]。 JIB-04(60,40和20mg / kg,ip)在小鼠脑中达到生物活性浓度。原位GB异种移植模型显示JIB-04治疗小鼠的生存期较长,危险比为0.5 [2]。 |
Cell Experiment | 对于细胞活力测定,将细胞以1500-3000个细胞/孔接种在96孔板中,并在第二天用增加剂量的化合物在4天内处理,并使用Promega的Cell Titer或Cell Titer-Glo试剂通过标准MTS测定评估其活力。 。通过Spectra Max或FlouroStar Omega读板仪测量490nm和650nm处的吸光度或发光。将数据标准化为未处理的对照(100%存活率)。每个细胞系在2-5个独立测定中进行测试,每个测定包含4-8个重复。 IC50值使用DIVISA计算,DIVISA是一种内部开发的高通量软件,用于存储和分析药物敏感性测定。使用非线性回归模型绘制剂量 - 反应曲线,并从拟合曲线确定IC 50。报道了来自2-5个独立测定的平均IC 50,每个测定含有4-8个重复。 |
Animal Experiment | 对于异种移植物,将4-6周龄雌性裸鼠在标准条件下饲养在UTSW的清洁设施中。皮下注射200万个H358细胞或500万个A549细胞,并在监测下生长2-3周。当肿瘤达到约200mm 3时,开始治疗,体重和肿瘤体积匹配对(每个细胞系的每个治疗组n = 7)。药物或赋形剂通过腹膜内注射在10%DMSO 90%芝麻油中每周2至3次,以110mg / kg给予所有携带H358异种移植物的小鼠5周或通过管饲在12.5%Cremophor EL中每周3次,12.5%DMSO,55mg / kg的含水悬浮液,含有A549异种移植物的小鼠。通过卡尺测量每周两次监测肿瘤体积。在治疗的五周期间称重并观察动物。在终点,通过CO 2窒息和颈椎脱位使小鼠安乐死,并收集血液,肿瘤和主要器官并称重。使用Excel软件在治疗组中进行配对,不等方差,单尾t检验。 |
Data Literature Source | [1]. Wang L, et al. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. Nat Commun, 2013. 4: p. 2035. [2]. Banelli B, et al. Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells. Oncotarget. 2017 Apr 4. |
Unit | Bottle |
Specification | 5mg 10mg |
是一种广谱的选择性Jumonji histone demethylase抑制剂。
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.